218772-92-0

Basic information

• Product Name: BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID
• Synonyms: TRANS-3-TERT-BUTOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID;trans-3-(Boc-aMino)cyclohexanecarboxylic acid, 97%;Cyclohexanecarboxylic acid, 3-[[(1,1-dimethylethoxy)carbonyl]amino]-, (1R,3R)-rel-;trans-3-(tert-Butoxycarbonylamino)cyclohexanecarboxylic acid≥ 99% (GC);rel-(1R,3R)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid
• CAS NO: 218772-92-0
• Molecular Formula: C12H21NO4
• Molecular Weight: 243.3
• Mol File: 218772-92-0.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 396.7°C at 760 mmHg
• Flash Point: 193.7°C
• Appearance: /
• Density: 1.12g/cm³
• Vapor Pressure: 2.12E-07mmHg at 25°C
• Refractive Index: 1.493
• CAS DataBase Reference: BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID(218772-92-0)
• EPA Substance Registry System: BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID(218772-92-0)

Safety Data

• Hazardous Substances Data: 218772-92-0(Hazardous Substances Data)

Usage

Description

BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID is a chemical compound with the molecular formula C9H16NO4. It is a white to off-white solid and is commonly used as an intermediate in pharmaceutical and chemical research.

Uses

Used in Pharmaceutical Industry:
BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID is used as an intermediate for the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Chemical Research:
BOC-TRANS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID is also used in chemical research as a starting material for the synthesis of various organic compounds. Its versatility and reactivity make it a valuable tool for chemists in exploring new chemical reactions and developing novel molecules with potential applications in various fields.

InChI:InChI=1/C12H21NO4/c1-12(2,3)17-11(16)13-9-6-4-5-8(7-9)10(14)15/h8-9H,4-7H2,1-3H3,(H,13,16)(H,14,15)/t8-,9-/m1/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 16636-51-4 3-aminocyclohexanecarboxylic acid 
• 34619-03-9 tert-butyldicarbonate 
• 851075-68-8 ethyl (1R,3S)-3-[(tert-butoxycarbonyl)amino]cyclohexanecarboxylate 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 
• 16636-51-4 (+/-)-cis-3-aminocyclohexanecarboxylic acid 
• 99-05-8 meta-aminobenzoic acid 
• 62059-56-7 cis-1,3-Cyclohexanedicarboxylic acid diethyl ester 
• 227783-08-6 (1S,3R)-3-ethoxycarbonylcyclohexane-1-carboxylic acid 
• 1312544-21-0 C₈H₁₁N*C₁₂H₂₁NO₄ 
• 121-92-6 3-nitrobenzoic acid 
• 862401-49-8 cis-3-aminocyclohexanecarboxylic acid hydrochloride 
• 227783-03-1 (1S,3R)-Cyclohexane-1,3-dicarboxylic acid monoethyl ester 
• 218772-92-0 (±)-cis-3-((tert-butoxycarbonyl)amino)cyclohexanecarboxylic acid 

Downstream Products

• 174893-22-2 cis-1,3-cyclohexanedi(tert-butoxycarbonyl)amine 
• 1261225-48-2 [3-(1S,3R)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 1261225-49-3 [3-(1R,3S)-benzyloxycarbonylaminocyclohexyl]-1-carbamic acid tertbutyl ester 
• 222530-39-4 (1R,3S)-3-(tert-butoxycarbonylamino)aminocyclohexanecarboxylic acid 
• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 
• 1607590-84-0 tert-butyl (3-formylcyclohexyl)carbamate 
• 920966-16-1 tert-butyl [3-(hydroxymethyl)cyclohexyl]carbamate 
• 1607590-85-1 tert-butyl {3-[2-cyanovinyl]cyclohexyl}carbamate 
• 1607590-86-2 3-(3-aminocyclohexyl)acrylonitrile hydrochloride 
• 1607590-87-3 3-{3-[(6-nitrothieno[3,2-b]pyridin-7-yl)amino]cyclohexyl}acrylonitrile 
• 1607590-88-4 3-{3-[(6-aminothieno[3,2-b]pyridin-7-yl)amino]cyclohexyl}propanenitrile 

Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human

The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.